Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind active-controlled Phase IV safety comparison study of freeze-dried Japanese encephalitis vaccine (Vero cell), inactivated
CTR20240927Phase 4Completed
- Sponsor
- Liaoning Chengda Biotechnology Co., Ltd.
- Start
- Mar 2024
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Japanese encephalitis vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Liaoning Chengda Biotechnology Co., Ltd. Primary endpoints: Incidence, severity, and relatedness of any adverse events within 30 minutes after vaccination, Incidence, severity, and relatedness of solicited adverse events within 0–7 days after vaccination and 2 more. Started Mar 2024; status: completed.
02
Drugs
Japanese encephalitis vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on CTR20240927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240927.